Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial

View ORCID ProfileAlben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt
doi: https://doi.org/10.1101/2020.12.03.20238840
Alben Sigamani
1Group Head, Clinical Research, Narayana Health, Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alben Sigamani
  • For correspondence: alben.sigamani.dr@narayanahealth.org
Samarth Shetty
2Consultant, Mazumdar Shaw Medical Center, Narayana Health, Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhavi
2Consultant, Mazumdar Shaw Medical Center, Narayana Health, Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathu Ruthra
3Department of Clinical Research, Narayana Health Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudhishma
3Department of Clinical Research, Narayana Health Bangalore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anup Chugani
4MedGenome Laboratories
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana Chen-Walden
5Medical Officer, Pharmalectin Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ThomasKutty
6Clinical Perfusionist Baylor Scott& White Health,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomaskutty.alumparambil@bswhealth.org
David Platt
7Chief Chemist, Pharmalectin Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Novel SARS-CoV-2 virus has infected nearly half a billion people across the world and is highly contagious. There is a need for a novel mechanism to block viral entry and stop its replication.

Background Spike protein N terminal domain (NTD) of the novel SARS-CoV-2 is essential for viral entry and replication in human cell. Thus the S1 NTD of human coronavirus family, which is similar to a galectin binding site - human galactose binding lectins, is a potential novel target for early treatment in COVID-19.

Objectives To study the feasibility of performing a definitive trial of using galectin antagonist – Prolectin-M as treatment for mild, symptomatic, rRT-PCR positive, COVID-19.

Main outcomes and measures Cycle threshold (Ct) value is number of cycles needed to express fluorescence, on real time reverse transcriptase polymerase chain reaction. Ct values expressed for RNA polymerase (Rd/RP) gene +Nucleocapsid gene and the small envelope (E) genes determine infectivity of the individual. A digital droplet PCR based estimation of the Nucleocapid genes (N1+N2) in absolute copies/μL determines active viral replication.

Design and intervention Pilot Feasibility Randomised Controlled Open-Label, parallel arm, study. Oral tablets of Prolectin-M were administered along with the best practice, Standard of Care (SoC) and compared against SoC. Voluntarily, consenting individuals, age >18 years, and able to provide frequent nasopharyngeal and oropharyngeal swabs were randomly allocated by REDCap software.

The intervention, Prolectin-M was administered as a multi dose regime of 4 gram tablets. Each tablet contained 2 grams of (1-6)-Alpha-D-mannopyranosil mixed with 2 grams of dietary fibre. Each participant took a single chewable tablet every hour, to a maximum of 10 hours in a day. Tablets were administered only during the daytime, for total of 5 days.

Results This pilot trial demonstrated the feasibility to recruit and randomize participants. By day 7, following treatment with Prolectin-M, Ct value of Rd/Rp + N gene increased by16.41 points, 95% (CI – 0.3527 to 32.48, p=0.047). Similarly, small envelope (E) gene also increased by 17.75 points (95% CI;-0.1321 to 35.63, p = 0.05). The expression of N1, N2 genes went below detectable thresholds by day 3 (Mann Whitney U = 0.000, p<0.029).

rRT-PCR testing done in the clinic on day 1, 7, and 14 had 3 participants (60%) turn negative by day 7 and all turned negative by day 14 and stayed negative until day 28. In the SoC group 2 participants had zero detectable viral loads at baseline, 2 participants tested negative on day 14, and the last participant tested remained positive on day 28. There were no serious adverse events, and all participants were clinically asymptomatic before day 28 with reactive immunoglobulin G (IgG).

Trial relevance This pilot study proves that it is feasible and safe to perform a trial using a Galectin antagonist in COVID-19. This is a novel mechanism for blocking viral entry and its subsequent replication.

Trial Registration Clinical Trials.gov identifier NCT04512027; CTRI ref. CTRI/2020/09/027833

Competing Interest Statement

This trial was funded by Pharmalectin and all authors were supported under this grant.

Clinical Trial

NCT04512027; CTRI ref. CTRI/2020/09/027833

Funding Statement

This trial was fully sponsored by the manufacturers of Galectin antagonist prolectin-m The funding was provided by Pharmalectin Inc

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study protocol and all documents were reviewed by Institutional Ethics Committee;Narayana Health and approved (NHMEC Ref. No. S44/ 2020), on 31st of August 2020. The study was conducted in compliance with the Declaration of Helsinki, the Good Clinical Practice guidelines, and local regulatory requirements.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Edits were made to align the text to increase our chances of landing the paper to peer reviewed journal. Certain text in the results was modified for clarity.

Data Availability

This is a pilot and feasibility trial. The data is available in a secure database and is locked within a REDCap electronic database.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 09, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial
Alben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt
medRxiv 2020.12.03.20238840; doi: https://doi.org/10.1101/2020.12.03.20238840
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial
Alben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt
medRxiv 2020.12.03.20238840; doi: https://doi.org/10.1101/2020.12.03.20238840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (412)
  • Dentistry and Oral Medicine (68)
  • Dermatology (47)
  • Emergency Medicine (142)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4843)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (674)
  • Geriatric Medicine (70)
  • Health Economics (191)
  • Health Informatics (625)
  • Health Policy (318)
  • Health Systems and Quality Improvement (203)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5322)
  • Intensive Care and Critical Care Medicine (328)
  • Medical Education (93)
  • Medical Ethics (25)
  • Nephrology (75)
  • Neurology (685)
  • Nursing (42)
  • Nutrition (113)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (205)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (777)
  • Public and Global Health (1810)
  • Radiology and Imaging (323)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)